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Abstract
Over the past two decades, increased global incidence of malignancy, improved sys-
temic disease treatment with prolonged survival, and increased central nervous system 
(CNS) surveillance in cancer patients have all contributed to a rise in cerebral metastatic 
disease. As many patients retain good neurologic function, the approach to their man-
agement has shifted markedly; a pre-terminal prognosis and palliative treatment have 
been replaced by individualized care plans to prolong functional survival. However, the 
rapid shifts in disease characteristics, treatment options and emerging evidence can be 
challenging to navigate, and a rational approach to brain metastases is needed. We dis-
cuss the changing epidemiology of brain metastases and consider approaches to prog-
nostic classification. We review current treatment modalities and discuss the significant 
studies pertaining to each, with emphasis on Level 1 evidence when available and coop-
erative group trials, as well as studies on adverse effects. To integrate the information 
presented, we offer case scenarios that highlight pertinent decision-making factors. The 
shift in care goal for cerebral metastases from symptom palliation to prolongation of 
survival is not only feasible, but in many cases indicated. The appropriate application 
of various treatment modalities must be considered in the context of individual patients 
and their primary cancer.
Keywords: brain metastases, surgery, whole-brain radiation, stereotactic radiosurgery, 
targeted therapy
1. Introduction
Brain metastases are the most frequent intracranial neoplasm in adults, and the most common 
intracranial metastatic site is the brain parenchyma [1–3]. Historically, intracranial dissemina-
tion represented a poor prognosis for cancer patients, best supportive care leading to an over-
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all survival around 1–2 months [4]. Advances in systemic cancer management, however, as 
well as in local treatments for cerebral disease, have greatly altered the prognosis and survival 
for patients. Brain metastasis management is therefore an emerging area of interest in organ-
specific metastasis research addressing standard protocols for local management, includ-
ing rational use of surgical resection, stereotactic radiosurgery (SRS), adjuvant or exclusive 
whole-brain radiotherapy (WBRT), and emerging systemic therapies. As survival increases, 
considerations for maintenance of neurocognitive function and quality of life gain greater 
importance. Decision-making for treatment of brain metastasis patients should be carried out 
in a multi-disciplinary setting, incorporating expertise from surgeons, oncologists, radiation 
oncologists, psychologists, and rehabilitation therapists.
2. Epidemiology of brain metastases
A single brain metastasis refers to the presence of only one parenchymal lesion in the context 
of an active primary cancer and possible extracranial metastases. In contrast, solitary brain 
metastasis describes the presence of only one parenchymal deposit with controlled primary 
tumour and no other metastatic disease. A synchronous brain metastasis is one that is identi-
fied at the time of presentation of the primary cancer, while a precocious one presents prior 
to the primary malignancy.
The accurate global incidence of brain metastasis based on population study is unknown, 
with estimates ranging around 7–14 per 100,000 [5]. Among cancer patients, estimates of 
prevalence range from 8.5 to 9.6% [6, 7]. These numbers are likely low, as they come from 
relatively old studies in which imaging or histology were often incomplete or which ignored 
cerebral disease in seriously ill patients with symptomatic advanced cancer [1]. Autopsy 
series report higher rates; a 1963 series found CNS metastases in up to 24% of patients [8], and 
in 1978, Posner and Chernick found that 15% of patients with cancer had parenchymal brain 
dissemination [9].
The incidence of brain metastases appears to be rising, with several contributing factors 
[2, 10]. First, the global incidence of cancer is climbing, but mortality rates are declining as a 
result of improved detection and treatment [1, 11]. New chemotherapeutic agents have led to 
a better prognosis and longer survival for many cancers, but fail to prevent central nervous 
system (CNS) spread due to low penetration of the blood–brain barrier, thus allowing greater 
opportunity for development of intracranial disease [1]. For example, the agent trastuzumab, 
a targeted therapy for HER2-positive breast cancer with presumed low CNS penetrance, has 
altered the natural history of this disease and may have unmasked the CNS as a sanctuary 
site [1]. In addition, improvement in surveillance, particularly due to greater diligence in fol-
lowing patients who have cancer and integrating brain MRI imaging into these follow-ups 
(64% today vs. 14% 20 years ago), has revealed more cerebral lesions prior to symptom devel-
opment. For instance, patients with a new diagnosis of small cell and non-small cell lung 
carcinoma (NSCLC) typically undergo routine screening brain MRI, and inclusion into many 
clinical trials requires negative screening brain MRI [2].
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The incidence and prevalence of brain metastases is also influenced by patient-specific 
 factors, such as race or site of primary tumour. African-Americans with lung, melanoma, 
or breast cancer, but not renal cancer, appear at greater risk of developing brain metastases 
than Caucasians [6, 12]. However, confounders such as variability in healthcare access and 
awareness may account for some racial differences.
Although any neoplasm can potentially disseminate to the brain, certain primary histolo-
gies exhibit a higher propensity to do so; a population-based study from the Metropolitan 
Detroit Cancer Surveillance System found that 19.9% of lung, 6.9% of melanoma, 5.1% of 
breast, 6.5% of renal, and 1.8% of colorectal cancers develop brain metastases [6]. The preva-
lence of the primary tumour also affects the incidence of cerebral disease; thus 39–56% of 
brain metastases arise from lung, 13–30% from breast, 6–11% from melanoma, 2–6% from 
renal, and 3–4% from colorectal cancers [13–15]. Of note, in 10% of cases, no primary cancer 
can be identified [3]. The histology of the primary tumour is a key determinant in almost all 
epidemiological aspects of brain metastasis, including incidence, time interval from diagnosis 
of primary tumour to occurrence of intracranial spread, prognosis, and survival. In addition, 
the influence of molecular and genetic features is being increasingly recognised. For instance, 
the occurrence of cerebral dissemination varies according to the molecular subtype of breast 
cancer: the incidence for patients with triple-negative tumours [human epidermal growth 
factor receptor-2 (HER2) non-overexpressed, and oestrogen and progesterone receptor (PR) 
non-expressed] is 25–46%; whereas, it is 7.6% for patients with luminal tumour A (HER2 
non-overexpressed, oestrogen and progesterone receptors expressed, and low proliferation 
index) [3].
Although a specific gender susceptibility might exist, the primary tumour type is thought to 
play an important role in the fact that the incidence of brain metastasis is higher in women 
than men. The increasing incidence of lung cancer in women and the propensity of breast 
tumours to metastasise to the brain have contributed to reverse the trend of 20 years ago, 
when more males were diagnosed with brain metastases [6, 16].
The median age at diagnosis has remained fairly stable for the past 20 years, ranging from 
57 to 63 years [1]. Primary cancer influences the age at diagnosis: lung cancer, 40–49 years; 
melanoma, renal, and colorectal cancer, 50–59 years; breast cancer, 20–39 years. The higher 
frequency of cerebral metastases in younger and/or African-American women with breast 
cancer could be explained by the larger number of triple-negative tumours in this population, 
a subtype associated with a high risk of CNS progression [1].
Brain metastasis remains associated with advanced cancer, and over the past 20 years the 
proportion of patients with intracranial spread who also harbour extracranial metastases has 
increased (44 vs. 14%). [17]. The number of patients presenting with only one brain metastasis 
has fallen from 63 to 29%, while the proportion of patients with three or more lesions has 
increased from 17 to 36%. In addition, detection of synchronous brain metastases, at diagnosis 
of primary tumour, is also more frequent (from 18 to 30%) [17]. These changes are likely due 
to the increased use of brain MRI imaging. At the same time, the median time interval from 
diagnosis of primary tumour to detection of cerebral metastasis has increased from 3 to 8 
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months, depending on the site of primary tumour: 2.6–7 months for lung cancer as opposed 
to 39–47 months for breast cancer [1].
The increase in concurrent extracranial metastases directly impacts the assessment of prog-
nosis; the Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis (RPA) 
classification correlates clinical factors with median survival [18]. The most favourable prog-
nosis, with median survival of 7.1 months, is seen in Class 1 patients who have a Karnofsky 
performance score (KPS) of ≥70, age <65, and controlled primary tumour without extracranial 
metastases. Class 3 patients have KPS <70 and a median survival of 2.3 months and are con-
sidered poor prognosis. All other patients fall into Class 2, including those with KPS ≥70 but 
other unfavourable characteristics, such as uncontrolled primary tumour, extracranial metas-
tases, or age ≥65; these have a median survival of 4.2 months. The past two decades have seen 
a shift in patients away from both the most favourable (19 to 7%) and most unfavourable (44 
to 31%) classes to the intermediate class [17–19].
It is well-recognised that primary tumour type influences median survival, with ranges 
including 2.7–6.3 months for lung, 5.1–6 months for colorectal, and 4.8–10 months for mela-
noma. In addition, survival for breast cancer differs according to histological and molecular 
subtypes; median survival for inflammatory breast cancer is 2.9 months, triple-negative is 
4.9 months, HER2 overexpressing receiving trastuzumab is 11.3–26.3 months, and hormone 
receptor-positive is 19–24 months [1]. The diagnosis-specific graded  prognostic assessment 
(DS-GPA) further incorporates prognostic variables significant to particular primary tumours; 
for instance, while age, KPS, the presence of extracranial metastases and number of brain 
metastases are seen to influence survival in lung cancer, and age, KPS and receptor subtype 
affect breast cancer survival, only KPS and number of BM were significant factors in mela-
noma and renal cell cancer and only KPS in gastrointestinal cancer survival [20].
Accurate prognostic information is useful to optimise treatment for patients who may gain 
months to years of survival following intracranial progression and to avoid overtreating 
patients who will derive little benefit. A contemporary cohort of brain metastasis patients 
who received more local (surgical resection and stereotactic radiosurgery) and systemic (che-
motherapy and targeted therapy) treatment compared with a historical cohort had minimal 
improvement in median survival (3.2 vs. 3.9 months). However, 1-year survival increased 
from 15 to 34%, increased survival was seen at all time points during follow-up, and some 
long-term survivors were observed [17]. Survival was dependent on presenting symptoms of 
brain metastasis and treatment received.
Improvements in local procedures, along with increasing availability of systemic therapies, 
have altered the prognosis for patients with brain metastases.
3. Overview of brain metastasis management
Brain metastasis is a devastating sequela of cancer and develops in 25–40% of that patient 
population [21–23]. It is associated with a high morbidity and mortality; without treatment, 
median survival after diagnosis is approximately 1 month [24]. Treatment options include 
whole-brain radiation therapy (WBRT), surgical resection, stereotactic radiosurgery (SRS), 
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and systemic therapies. With maximal management the overall survival rate increases to 
10–12 months, although some patients demonstrate a remarkable response to treatment [21, 
23, 24]. As a result, there is an ongoing debate regarding the most effective treatment regimen.
Not all brain metastases are equal, and there are many factors to consider when deciding on 
an appropriate treatment plan. Brain metastases can be categorised as solitary, single, or mul-
tiple. Furthermore, patients can be classified by type of primary tumour, status of systemic 
disease, functional status, and age to determine their prognosis, using such systems as the 
Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis (RPA), or diag-
nosis-specific graded prognostic assessment (DS-GPA). Evaluation of these factors is impor-
tant in identifying patients who will likely benefit most from aggressive treatment, as well as 
avoiding overtreatment of patients who are unlikely to benefit. In patients with a favourable 
prognosis (RPA class 1, some class 2), increasing overall and functional neurological survival 
are reasonable goals and thus focal therapies form a major component of treatment, and out-
come assessment includes neurocognition and quality of life. In patients with an unfavour-
able prognosis, management focuses on symptom palliation as needed.
3.1. Whole-brain radiation therapy
WBRT was historically the treatment of choice for brain metastases, given that it was nonin-
vasive and provided symptom relief and a modest survival benefit to a group of patients with 
few options. In most centres presently, it is used for patients with an unfavourable prognosis 
due to their extracranial disease or high burden of brain metastasis, or poor functional status. 
It is also used as adjuvant to focal treatment modalities (surgery or SRS), in order to reduce 
local recurrence and development of distant metastases, as well as salvage therapy on intra-
cranial recurrence.
Over 70% of patients diagnosed with brain metastasis have multiple brain lesions at the time 
of diagnosis [21, 23]. The primary goals of treatment are to palliate symptoms and maintain 
neurologic function, and in some cases to increase survival, by treating the existing lesions and 
decreasing the volume of micro-metastases. The RTOG showed that approximately 50% of 
patients experienced neurological improvement by 2 weeks after initiation of WBRT. Median 
survival was 15–18 weeks, and 21 weeks in patients who were ambulatory [25]. Surprisingly, 
the dosing regimen did not affect survival [25, 26]. The typical radiation schedule involves a 
7–15-day course of whole-brain radiation with 1.5–4 Gy per fraction. In some circumstances, 
a single fraction of 6–8 Gy or a bi-weekly fractionation regimen may be appropriate, such 
as when multiple treatment sessions may be impractical for a debilitated patient or unfea-
sible due to resource constraints. Such protocols may result in both inferior control rates and 
increased neurocognitive adverse effects, so should be applied with caution. Not all tumour 
histologies respond equally to radiation therapy; small cell lung cancer, germ cell tumours 
and hematologic malignancies are highly radiosensitive, while renal cell carcinoma, mela-
noma, and sarcoma are relatively radioresistant.
Acute adverse effects of WBRT include hair loss, nausea, vomiting and increased cerebral 
oedema with worsening of neurological symptoms. Concerns about long-term neurocogni-
tive effects have been raised over the past two decades, especially as survival for patients 
with metastatic cancer is increasingly prolonged. A 1989 retrospective review found that 
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1.9–5.1% of patients who underwent WBRT developed progressive dementia, ataxia, and uri-
nary incontinence causing significant morbidity [27]. Although most patients who developed 
these complications were given 5–6 Gy per fraction, a dose much higher than what is usually 
given today, a decline in memory and learning function is recognised in patients treated with 
typical fractionation protocols for WBRT, detectable between 6 and 12 months after treatment 
and not reversible [28]. Yet patients with brain metastases have detectable neurocognitive 
decline even prior to any treatment, indicating that cognitive changes may be attributable 
to the presence of tumour [29] and that failure to control metastatic brain disease also has 
a significant adverse impact on neurocognitive function [30]. Recent studies have explored 
strategies to reduce the toxicity of treatment, such as hippocampal-avoidance WBRT, which 
uses intensity-modulated radiotherapy (IMRT) to reduce the radiation exposure of the hip-
pocampal neural stem cell niche important to memory function. A phase II study found 
reduced decline in Hopkins Verbal Learning Test-Revised Total Recall (HVLT-R TR), with 
low progression of disease within the hippocampal avoidance area, compared with histori-
cal controls [31]. Other approaches include use of the NMDA receptor antagonist memantine 
during and following WBRT administration; a small randomised controlled trial of meman-
tine vs. placebo did not show a difference in the primary endpoint of memory decline (as 
measured by HVLT-R Delayed Recall), but did demonstrate longer time to cognitive decline 
[32]. The effectiveness of neuroprotective strategies and indeed the optimal modalities for 
neurocognitive testing remain areas of study.
3.2. Surgery
Surgical resection is considered for patients with a single symptomatic lesion in an accessible 
location, with the goal of reducing mass effect (e.g. to improve neurologic deficit or reduce 
seizures), decreasing tumour burden, and obtaining a tissue diagnosis when brain metastasis 
is in the differential diagnosis.
Level 1 evidence provides support for effectiveness of surgery in single metastatic brain 
lesions in patients with good functional status and controlled systemic disease. Patchell et al. 
randomised 48 patients into 2 groups (surgery + WBRT vs. needle biopsy + WBRT) and found 
that overall survival was higher in the surgical group, with a mean survival of 40 weeks com-
pared to 15 weeks (p < 0.01). There was also a lower incidence of recurrence in the  surgical site 
and longer functional independence [33]. This was supported by the results of Vecht et al., 
who also found improved overall and functionally independent survival with surgery + 
WBRT vs. WBRT alone in patients with good functional status and controlled extracranial dis-
ease; when there was active extracranial disease, the median survival was 5 months regardless 
of treatment [34]. In contrast, Mintz et al. found no significant difference in survival between 
the surgical and non-surgical groups [35]. However, the patient population in this study had 
a higher percentage of active systemic disease and lower functional status, compared to the 
other studies; these randomised controlled trials together emphasise the influence of these 
prognostic factors.
The surgical treatment of multiple brain metastases is more controversial. These patients tend 
to have greater systemic disease burden and are generally expected to have a short survival, 
so aside from the occurrence of a large lesion or one causing significant mass effect, they 
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are regarded as poor candidates for surgical resection. A case-controlled study by Bindal et 
al. showed that the mean survival of patients who had all of 2 or 3 lesions resected was sig-
nificantly longer than that of patients who underwent incomplete resection and was similar 
to that of patients who had a single metastasis that was resected [36]. However, this study 
did not control for the number and locations of lesions. In contrast, Paek et al. did not iden-
tify a difference in survival among patients who underwent resection of one versus two or 
three metastases [37]. Iwadate et al. found that total residual tumour quantity, rather than 
lesion number, was a significant predictive factor; an improvement in survival from 4.5 to 
12.4 months was seen when patients with multiple brain metastases underwent a total or 
subtotal resection with cumulative residual tumour <2 cm (p < 0.05) [38]. Taken together, these 
observational studies and conflicting results do not support resection of multiple metastases 
for the purpose of tumour control.
Following surgical resection, local recurrence is common and adjuvant radiotherapy aims to 
eliminate tumour cells remaining within the tumour bed, as well as to reduce micro-metasta-
ses in other locations throughout the brain. However, while multiple retrospective series have 
shown that WBRT does decrease distant recurrence, it confers no survival benefit [39–41]. In 
a randomised controlled trial comparing surgery vs. surgery + WBRT for a single metastasis, 
adjuvant WBRT reduced the local recurrence rate from 46 to 10% (p < 0.001), distant recur-
rence from 37 to 14% (p < 0.01), and decreased the likelihood of death from neurological 
causes. Remarkably, WBRT reduced the rate of total intracranial progression from 70 to 18% 
(p < 0.001), but there was no overall survival benefit or difference in duration of functional 
independence [42]. The EORTC 22952 randomised controlled trial evaluated adjuvant WBRT 
vs. observation following local treatment, either surgical resection or radiosurgery. The prob-
ability of local and distant relapse was significantly reduced in the WBRT arm, after both 
surgery and SRS. Survival with functional independence (WHO performance status > 2) and 
overall survival did not differ between the two arms, and initial treatment (surgery or SRS) 
was not a significant factor [43].
Radiosurgery to the resection cavity following surgical excision has become increasingly 
 utilised in order to spare the use of WBRT. Multiple retrospective series showed improved 
local control with the addition of adjuvant SRS to surgery, with rates comparable to adjuvant 
WBRT [44–46]. The first prospective study included 50 resection cavities, of which 40 received 
SRS and 10 were observed, and found a significantly lower rate of local failure in the SRS 
group (15 vs. 50%, p = 0.008) [47]. An ongoing phase III study through the Alliance for Clinical 
Trials in Oncology aims to provide level 1 evidence on this issue, randomising to WBRT or 
SRS patients with ≤4 metastases who have had ≥1 tumour resected. The primary endpoints 
will include overall survival and neurocognitive progression. As it stands, the high rate of 
local recurrence following surgery warrants adjuvant radiation, and the low morbidity of SRS 
to the tumour bed favours this combination of treatments to improve local control.
3.3. Stereotactic radiosurgery
In recent years, more patients are being managed with stereotactic radiosurgery, a non-invasive 
option for focal treatment of metastatic brain tumours. This technique was originally devel-
oped by Lars Leksell and utilises multiple convergent radiation beams on a tumour to deliver 
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a highly focused and concentrated dose. It has the advantage of exhibiting a steep radiation 
dose drop-off outside the tumour border, thereby reducing radiation exposure to surrounding 
tissue. Metastatic brain tumours tend to be lesions with discrete borders and spherical shape, 
often less than 3 cm in size, making them ideal candidates for SRS. Its non-invasiveness allows 
SRS to treat lesions in surgically inaccessible locations, as well as multiple lesions in a single 
outpatient session. Additionally, its efficacy is similar among relatively radio-resistant histolo-
gies such as renal cell carcinoma and melanoma, compared to radiosensitive tumour types. 
A minimal marginal dose of 18 Gy is associated with improved local control [48], and dose 
prescriptions generally range 18–25 Gy, lower doses being favoured in the brainstem and other 
eloquent locations, and when combined with WBRT. It does not reduce mass effect, however, 
and toxicity and local failure increase with increasing tumour size. While the acute effects of 
SRS are generally well-tolerated, the most common delayed complication is radiation necrosis, 
which may occur in up to 10% of tumours, 6 months to several years after treatment. Radiation 
necrosis develops more frequently with higher radiation dose, following prior stereotactic or 
fractionated radiation treatment, in larger tumours, and possibly when SRS is combined with 
targeted or immune therapy [49]. Distinguishing treatment effect from tumour recurrence 
is necessary but challenging, as both can exhibit increased enhancement and peri-lesional 
oedema, and advanced imaging techniques such as perfusion MRI and amino acid PET are 
under investigation to increase diagnostic specificity. Treatment is largely symptomatic, with 
corticosteroids. Observational studies have explored treatment for severe cases including 
resection, laser interstitial thermal therapy, bevacizumab, or hyperbaric oxygenation [50].
The efficacy of SRS was demonstrated in a randomised controlled trial carried out by 
Kondziolka et al., which compared WBRT plus a single-dose radiosurgery boost to WBRT 
alone in patients with 2–4 brain metastases. At a planned interim analysis, the primary end-
point of local control so strongly favoured combination treatment that the study was stopped 
(p = 0.0016). This left it underpowered to demonstrate a difference in overall survival. At one-
year follow-up, the rate of local failure was 100% in patients treated only with WBRT, com-
pared to 18% in those who had received SRS boost (p = 0.002) [51]. The subsequent RTOG 9508 
randomised controlled trial also comparing WBRT plus SRS to WBRT alone in patients with 
1–3 tumours found that the primary endpoint of median survival was met in the combined 
treatment arm, but only in patients with a single lesion (6.5 vs. 4.9 months, p = 0.04). The 
 secondary endpoints of local control and improvement in performance status were met in the 
whole treatment cohort [52]. A secondary analysis of this data by Sperduto et al. that strati-
fied patients by GPA found that WBRT + SRS conferred a survival benefit in good-prognosis 
patients (GPA 3.5-4) even with >1 lesion [53]. As with surgery, these studies emphasise the 
significant prognostic effect of good pre-treatment function and controlled systemic disease.
In comparing stereotactic radiosurgery with surgical resection, multiple retrospective studies 
have shown comparable survival, with some suggesting improved local control for SRS [54, 
55], others favouring surgery [56], and still others suggesting a similar local control rate for 
the two modalities [57]. A single randomised controlled trial comparing surgery + WBRT with 
SRS was stopped prematurely due to poor accrual; the data acquired showed similar rates of 
local recurrence, overall survival and neurological death between the two arms [58]. Overall, 
the data suggest that SRS is at least as effective as surgery for tumour control and given the 
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collective experience with its safety and utility, in the absence of a specific surgical indication 
such as a large or symptomatic lesion or uncertain diagnosis, is appropriate as first-line treat-
ment for 1–3 newly diagnosed brain metastases.
The use of adjuvant WBRT for SRS has been controversial, and several randomised controlled 
trials have compared SRS with adjuvant WBRT to SRS alone. Similarly to the EORTC 22952 
results, the Japanese Radiation Oncology Study Group found no significant difference in the 
primary endpoint of overall survival, or in functional preservation, despite significant reduc-
tion in local and distant recurrence in the WBRT arm [59]. In a single-institution RCT, Chang 
et al. evaluated a primary endpoint of cognitive function as determined by HVLT-R TR. 
A planned interim analysis at 4 months found a higher rate of total recall deterioration in 
the SRS + WBRT arm, and the trial was therefore halted. At study conclusion, overall intra-
cranial recurrence was reduced in the WBRT arm, but a survival benefit was seen in the SRS-
alone arm, a difference from other studies that the authors attributed to salvage therapies 
[60]. A cognitive primary endpoint was evaluated in the multi-institutional study of Brown et 
al., deterioration defined as decline of >1 standard deviation on ≥1 of 7 instruments assessing 
a range of cognitive domains. Cognitive deterioration was significantly worse in the WBRT 
arm, as were quality of life measures. Intracranial relapse was significantly greater in the 
observation arm, but overall survival was not different [61]. The evidence supports consider-
ation of close observation for intracranial progression following SRS for 1–3 metastases, with 
salvage therapy at that time, to avoid routine use of adjuvant WBRT.
Earlier series limited the use of SRS to ≤4 lesions, a restriction that was largely technical rather 
than biological, and currently multiple lesions can be easily treated in a single session. Yet 
the evidence that guides treatment of a few lesions cannot necessarily be extrapolated to the 
management of many tumours; for instance, although SRS is highly conformal, with increas-
ing tumour number the intervening brain is exposed to more radiation. In addition, some 
series suggest that the number of tumours is less important than the total tumour volume. 
A prospective observational study in patients with 1 to 10 brain metastases treated with SRS 
found that patients with a single lesion experienced significantly longer survival, but showed 
no  difference in survival between patients with 2–4 and 5–10 tumours [62]. These latter groups 
also showed no difference in local or distant failure, suggesting that up-front use of SRS may be 
as appropriate for ≥5 lesions as for ≤4. An ongoing trial through the North American Gamma 
Knife Consortium aims to shed light on the neurocognitive outcome of patients with multiple 
metastases randomised to either SRS or WBRT. Included are patients harbouring ≥5 lesions, 
with no maximum number but total tumour volume restricted to 15 mL. This study will addi-
tionally evaluate patient- and caregiver-assessed quality of life, and include a cost analysis.
At the time of intracranial progression, repeat SRS may be considered in patients who main-
tain a good functional status and controlled systemic disease. Imaging suggestion of local 
recurrence must be distinguished from treatment effect, and especially if minimally symp-
tomatic, a conservative approach with serial imaging is generally warranted before repeat 
treatment. Risk factors for local recurrence may include larger tumours, lower marginal dose, 
and melanoma histology. Multiple retrospective series have shown efficacy for SRS in new 
or recurrent tumours, including after WBRT, with adjustment to lower fraction dose in the 
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setting of prior radiation exposure. These series suggest a local control rate comparable to 
first-time SRS [63–65].
3.4. Systemic therapy
The use of cytotoxic chemotherapy in treatment of brain metastases has historically been lim-
ited due to the perception that the blood–brain barrier isolates tumour cells from circula-
tion agents. Furthermore, these patients usually have already been heavily pre-treated with 
conventional chemotherapy for their primary cancer, this prior exposure leading to tumour 
resistance against many agents. In addition, death from progression of systemic disease may 
preclude an assessment of the effect of the agent on intracranial disease. However, some 
phase II clinical trials have shown promising results for newer drugs in the treatment of cer-
tain subtypes of metastatic brain lesions [66]. The DNA-alkylating agent temozolomide has 
been widely studied for the treatment of brain metastases, in large part due to its high blood–
brain barrier penetrability. It has modest efficacy in monotherapy, but in combination with 
radiotherapy or other chemotherapeutic agents has demonstrated encouraging results, with 
up to 40% disease control in brain metastases from various primary sources as well as mini-
mal drug-related toxicity [67–69].
A meta-analysis of platinum-based chemotherapeutic agents (e.g. cisplatin) for small cell lung 
cancer demonstrated a 66% response rate for patients with brain metastases at initial diag-
nosis and 36% response rate for delayed brain metastases [70]. Unfortunately, most patients 
suffered from relapse of their disease or toxic side effects such as febrile neutropenia and sep-
sis [71]. In non-small cell lung cancer (NSCLC), these agents have shown a 28–45% response 
rate in chemotherapy-naïve patients [72]. Inhibitors of epidermal growth factor receptor 
(EGFR) have been approved for treatment of NSCLC due to the identification of frequent 
EGFR mutations in these tumours, and some retrospective series have demonstrated effect 
in brain metastases [73–76]. A phase II study of erlotinib in NSCLC patients with asymp-
tomatic brain metastases showed a 58% complete or partial response rate, including in some 
tumours without EGFR mutation. The median progression-free survival was significantly 
longer in mutant EGFR tumours than in wild-type tumours (15.2 vs. 4.4 months, respectively; 
p = 0.02) [77]. Other NSCLC tumours bear an oncogenic EMI4-ALK translocation, and 30% 
of these patients develop brain metastases [78]. The ALK-targeted tyrosine kinase inhibitor 
(TKI) crizotinib has demonstrated CNS penetration and effect, although patients invariably 
relapse [79]. Second-generation inhibitors of ALK may exhibit greater activity and durability 
of effect [80]. Combination of targeted agents with radiotherapy may be synergistic and yield 
improved response and survival, at the cost of increased adverse effects [81].
Patients with intracranial breast cancer metastases have response rates of 43–59% to cyclo-
phosamide with various combinations of 5-fluorouracil, methotrexate, and vincristine [72]. 
The molecular subtypes of breast cancer demonstrate different tendencies for brain dissemi-
nation, with triple-negative and HER2-positive tumours carrying the highest risk [82]. Routine 
treatment of the latter group of patients with HER2-directed therapy has markedly improved 
the overall prognosis, but a number of studies have shown an increase in brain metastases in 
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patients treated with trastuzumab [83]. This effect may be secondary to increased survival of 
patients with this agent and low permeability of the antibody through the blood–brain barrier 
[71, 72]. There is increasing interest in the role of agents such as lapatinib, a dual EGFR- and 
HER2-specific TKI, which has shown modest intracranial anti-tumour activity in phase II 
trials [84, 85]. In addition, the phase II LANDSCAPE trial evaluating the combination of lapa-
tinib and capecitabine, an inhibitor of DNA synthesis, demonstrated a 66% partial response 
and suggested that this systemic treatment may be an alternative to WBRT in HER2-positive 
patients [86]. Further randomised controlled trials are ongoing to explore the role for these 
and other systemic agents.
Cerebral metastases in melanoma historically carried a dismal prognosis. Cytotoxic chemo-
therapy is largely ineffective in management of metastatic melanoma, but new biologically 
active agents have dramatically altered the course of both intra- and extracranial disease for 
some patients. A phase II study of the anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) mono-
clonal antibody ipilimumab demonstrated a 24% tumour control rate in patients asymptomatic 
from brain metastases, and a 10% control rate in symptomatic patients on steroid therapy. The 
survival of patients with limited brain metastases on ipilimumab was similar to that of patients 
who did not have CNS disease [87]. In addition, occasional long-term responses have been 
observed with ipilimumab [88]. Dabrafenib, a small-molecule BRAF inhibitor, has shown effi-
cacy in melanoma containing a BRAF mutation; in a phase II trial, among melanoma containing 
the BRAF V600E mutation, an intracranial response was demonstrated in 39% of patients who 
had not previously undergone treatment for brain metastasis, and in 31% of patients who had 
progressive brain metastases after local treatment [89]. Even with bulky disease, BRAF inhibi-
tors can rapidly improve symptoms and control intracranial disease, although the response is 
generally short-lived. Investigations are ongoing into the optimal strategies for combining and 
incorporating these agents into management plans, as well as into other strategies.
4. Illustrative cases for evolving clinical considerations in brain metastases
Continued improvement in managing primary and systemic malignancy combined with 
greater sensitivity in detection of intracranial dissemination has increased the clinical burden 
of cerebral metastases. However, advances in therapy including refined surgical techniques 
and operative adjuncts, stereotactic radiation, and targeted systemic agents have shifted the 
goals of management from symptom palliation and modest survival increase to potentially 
long-term maintenance of neurologic function, cognitive independence, and quality of life. 
While progress is being made on many fronts, the array of treatment options also leads to 
many new areas of uncertainty. The cases below highlight some of the challenges currently 
faced by clinicians caring for patients with brain metastases.
Case 1: Whole-brain radiotherapy and neurotoxicity
A 47-year-old man develops headaches and clumsiness of his left arm. He has no signifi-
cant medical history and is employed as an accountant. MRI of the brain demonstrates 
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a right frontoparietal enhancing 3 cm mass with associated cyst, with surrounding vaso-
genic oedema (Figure 1A and B). CT scan of the body reveals a pulmonary nodule but no 
other lesions. Due to the neurologic symptoms, he undergoes craniotomy, and the intra-
cerebral lesion is metastatic adenocarcinoma consistent with lung primary. He makes sat-
isfactory recovery from surgery with improvement of neurologic function. He wishes to 
receive aggressive treatment for the brain metastasis but hopes to continue working as 
long as possible.
Randomised controlled trial data indicate that intracranial recurrence following surgical 
resection of a metastasis can be as high as 70%. This same study showed that adjuvant whole-
brain radiotherapy (WBRT) following surgery improves local control and decreases distant 
intracranial recurrence as well as neurologic mortality. Overall survival is unchanged [42]. 
Adjuvant WBRT following surgery is therefore recommended as a standard of management. 
However, many patients and physicians are increasingly concerned about the neurocognitive 
sequelae of WBRT, and some may wish to defer adjuvant WBRT in a patient with favourable 
prognostic factors (e.g. oligo-metastatic brain disease, good functional status, limited systemic 
disease) [27]. Retrospective studies report local control rates for SRS given to the tumour bed 
of a resected lesion that are comparable to post-operative WBRT [45, 46]. Patients must be 
counselled that intracranial progression also carries risk of neurocognitive deterioration.
In this case, SRS to the resection cavity would improve the rate of local control while sparing 
the neurocognitive adverse effects of whole-brain radiation. This patient requires close moni-
toring for the development particularly of new intracranial lesions.
Figure 1. Pre-treatment (A) T1 with gadolinium contrast and (B) T2 MRI at initial presentation, showing a single large 
right-sided mass with oedema and mass effect.
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Case 2: Local treatment of multiple metastases
A 52-year-old man presents with a 2-week history of word-finding difficulties and right 
leg weakness. He has a history of non-small cell lung cancer (NSCLC), negative for 
driver mutations, stage II at diagnosis, and treated 2 years prior. Four months ago, he 
received treatment for a single pulmonary metastasis, and on cytotoxic chemotherapy 
has demonstrated no recurrence. At this time, MRI of the brain shows two enhancing 
masses, a 3-cm medial left frontal lesion and a 3.5-cm left temporal tumour. The lesions 
are associated with extensive vasogenic oedema, and early uncal herniation is visible 
(Figure 2A and B).
Stereotactic radiosurgery is an acceptable first-line treatment for a limited number of cerebral 
metastases in patients with good function and controlled systemic disease. However, SRS 
does not reduce mass effect and may transiently worsen oedema, leading to increased neu-
rologic deficits.
Symptomatic mass effect is rapidly and effectively decreased with surgical tumour excision, 
but patients with multiple cerebral metastases are generally expected to have a short sur-
vival, so are considered poor candidates for surgery. Only retrospective series are available to 
address the issue, and the data are unclear as to whether the number of lesions or the total vol-
ume has a greater impact on outcome. Nevertheless, consideration of surgery may be made 
Figure 2. (A) and (B) Presenting T1 gadolinium contrast-enhanced MRI showing large left frontal and temporal lesions 
with oedema and mass effect.
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for a large, symptomatic lesion among multiple, or for a lesion in a high-risk location for mass 
effect such as the cerebellum or temporal lobe.
Treatment decisions must consider the whole patient and consider the systemic context of 
their disease. At times, a decision is made on a case-by-case basis with discussion between 
the multidisciplinary management team and the patient. In this case, whole-brain radiation 
may be favoured, although surgical resection of the symptomatic lesion may be considered 
for rapid relief of mass effect.
Case 3: WBRT: alone, adjuvant or not at all
A 63-year-old woman presents to the emergency department with new-onset generalised 
seizure. She had a neck melanoma treated with local excision 2 years prior. Antiepileptic 
medication controls the seizures, and she has a normal neurologic exam. MRI of the brain 
demonstrates four enhancing cerebral lesions as well as two cerebellar lesions (Figure 3A 
and B). CT and PET scan of the body demonstrate no other lesions.
WBRT has traditionally been the mainstay of treatment for multiple cerebral metastases, 
as it provided a modest survival benefit to patients with a poor prognosis and few options 
[25]. However, improved treatment of primary and metastatic malignancy has altered the 
prognosis for many patients, and better strategies to control intracranial progression as well 
as reduce the neurotoxicity of WBRT have been sought. This is particularly true for meta-
static melanoma, a disease with very poor prognosis that is also relatively radio-resistant. 
In patients with a limited number of brain metastases (≤4), randomised controlled trials 
Figure 3. (A) and (B) Presenting T1 with gadolinium contrast MRI showing multiple enhancing cerebral lesions.
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have demonstrated that addition of an SRS boost to WBRT improves local control compared 
to WBRT alone [51, 52]. More recently, a prospective series showed that multiple (2–10) 
tumours can be controlled with SRS alone, with no greater local or distant recurrence in 
patients with 5–10 lesions compared to 2–4 lesions [62]. Several randomised controlled tri-
als have also shown that adjuvant WBRT following SRS compared to SRS alone decreases 
the rate of intracranial relapse at local and distant sites, although overall survival is not 
affected [90].
For some histologies, systemic treatment may be considered as an upfront treatment or as 
adjuvant to a local modality. In a phase II study, ipilimumab immunotherapy demonstrated 
effect against metastatic melanoma with intracranial involvement [87]. A retrospective study 
showed no difference in survival among patients with metastatic melanoma with or with-
out intracranial involvement when treated with systemic ipilimumab [88]. Randomised con-
trolled trial data are not yet available to directly compare the efficacy of WBRT with systemic 
therapies.
In this case, WBRT remains an acceptable treatment, although first-line SRS with close imag-
ing follow-up may also be considered. Where available, immunotherapy may be offered.
Case 4: Radiation necrosis detection and management
A 56-year-old woman is referred for management of intracranial metastases identified on 
surveillance imaging (Figure 4A). She had HER2-positive breast cancer treated with mas-
tectomy, and has been on trastuzumab therapy for 10 months with satisfactory control of 
primary disease and no evidence of systemic metastasis. MRI of the brain shows two small 
lesions, and she receives SRS (21 Gy to each of the two lesions in a single fraction) and a 
course of WBRT (20 Gy in 10 fractions). Follow-up imaging demonstrates that the lesions 
have decreased in size, and no new lesions have developed (Figure 4B). Ten months after 
treatment, the patient begins experiencing morning headaches. On MRI, the lesions have 
expanded in size with more avid enhancement and are associated with increased oedema 
(Figure 4C and D).
Radiographic progression of lesions treated with SRS may be evidence of tumour progres-
sion or of treatment effect (i.e. radiation necrosis). Imaging modalities used to distinguish 
between these entities include CT-PET, MR spectroscopy, MR diffusion, and MR perfu-
sion. However, none of these techniques are yet definitive and clinical judgement and close 
imaging surveillance are indicated [91]. Radiation necrosis may occur in up to 50% of brain 
metastases treated with SRS [92–95], the risk increasing with larger target volume and frac-
tion dose [92, 96]. Changes may become evident on imaging 3 months to 3 years follow-
ing treatment, with a peak around 11 months. Pathological features include thrombosis and 
haemorrhage, fibrinous exudates and vascular fibrosis/hyalinization with luminal stenosis 
and occlusion. Congealed, fibrin-rich areas of gliosis contain dystrophic calcifications and 
macrophage infiltration. Excess extracellular proteolysis promotes cytokine activation and 
cytotoxic oedema, and other immune-mediated mechanisms may contribute to radiation-
induced neurotoxicity [97].
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The mainstay of treatment for symptomatic radiation necrosis is corticosteroids continued 
at the lowest effective dose until symptoms resolve [98]. In patients who develop adverse 
effects or are unable to tolerate corticosteroids, a small randomised placebo-controlled trial 
and some retrospective studies have shown that bevacizumab can be effective in reducing 
cerebral oedema and neurologic symptoms associated with radiation necrosis, as well as 
FLAIR and enhancement changes seen on MRI [99, 100]. While bevacizumab can markedly 
improve symptoms and imaging, adverse effects may include intracranial haemorrhage and 
wound healing complications should surgery become necessary, and careful patient selec-
tion is necessary [101]. In addition, several case reports and small series have suggested that 
Figure 4. (A) Pre-treatment gadolinium contrast-enhanced T1 MRI showing two left-sided metastases. (B) Gadolinium 
contrast-enhanced T1 MRI showing decrease in lesion size after treatment. (C) T1 gadolinium contrast-enhanced and 
(D) T2 MRI 10 months after treatment, showing increase in enhancing lesion size and peri-lesional oedema.
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hyperbaric oxygen (HBO) can also have a role in treatment of intracerebral radiation necro-
sis, with improvement in neurologic symptoms, decreased steroid requirement and reduced 
lesion size on imaging [102, 103].
Surgical resection should be considered in patients refractory or intolerant to corticosteroids, 
if the radiation necrosis has significant mass effect, or if imaging is equivocal and tumour 
progression remains a concern. If a lesion is not safely accessible, a biopsy may be considered 
to rule out active disease.
In this case, oedema causing mass effect and headaches can be treated with corticosteroids. 
As the diagnosis is uncertain, repeat imaging and clinical follow-up should be carried out in 
a short interval.
Case 5: Molecular profiling and targeted therapy
A 63-year-old man presents to the emergency department for evaluation following a motor 
vehicle collision. A single 6-mm lesion is identified in the right posterior midbrain, which 
demonstrates ring-enhancement on MRI (Figure 5). The patient’s past medical history is 
significant for melanoma treated with surgical excision 15 years prior.
In a patient who has undergone treatment for a cancer with a propensity for intracranial 
dissemination, a new brain lesion may be a metastatic deposit. However, in patients with 
a known primary malignancy, 11% may have a solitary brain lesion that is not metastatic 
[33]. Current imaging modalities have greatly improved the specificity of distinguishing brain 
metastases from primary tumours and other pathologies [104–106], but diagnostic certainty is 
essential to appropriate treatment planning and prognostication. In addition, some primary 
histologies include molecular subtypes that can benefit from targeted therapy, and patients 
who underwent diagnosis and treatment prior to the routine molecular profiling of such 
tumours may yet benefit from updated pathological analysis.
In melanoma containing the BRAF V600E mutation, the BRAF inhibitors dabrafenib [89] and 
vemurafenib [107] have demonstrated effect against brain metastases. The receptor tyrosine 
kinase inhibitors erlotinib and gefitinib show effect in NSCLC with an EGFR mutation [76], 
and crizotinib has shown some activity against NSCLC containing ALK rearrangement [79]. 
Furthermore, an alteration in oestrogen receptor (ER), progesterone receptor (PR) and HER2 
expression between primary and metastatic deposits is observed in >10% of breast cancers, 
requiring an alteration in management [108]. In patients who have HER2-postive tumours, 
a phase II trial demonstrated a 66% rate of objective CNS response for the combination of 
lapatinib and capecitabine [86].
In this case, the long latency period since the patient’s initial cancer presentation warrants 
histologic diagnosis of the cerebral lesion. In a deep location, needle biopsy would allow for 
safe extraction of diagnostic tissue.
Case 6: Prognostic considerations
A 78-year-old man who resides in a nursing home due to memory impairment undergoes 
evaluation for recurrent falls. MRI of the brain demonstrates atrophy and white matter 
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changes as well as numerous enhancing lesions suggestive of metastatic deposits (Figure 6). 
Systemic work-up reveals a rectal mass, as well as extensive retroperitoneal lymphadenop-
athy and a hepatic lesion, consistent with metastatic colorectal carcinoma.
The RTOG recursive partitioning analysis (RPA) identified Karnofsky performance status 
(KPS) as a key prognostic factor in patients with brain metastases [18]. The diagnosis-specific 
graded prognostic assessment found that certain RPA factors were not significant for some 
primary histologies, but KPS retained significance in all diagnoses [109]. In a patient with 
poor functional status, aggressive treatment of brain metastases is not indicated due to a 
short expected survival. WBRT may be offered to palliate neurological symptoms caused 
by intracerebral lesions and associated oedema. A radiographic response is seen in 40–60% 
of patients, with neurologic improvement in 25–40% [25, 52]. Observational studies  suggest 
Figure 5. Gadolinium contrast-enhanced T1 MRI of incidentally found midbrain lesion.
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an improvement in survival compared to corticosteroids/supportive therapy [110, 111]. 
However, radiotherapy requires daily treatment sessions for 10–15 days, and acute radiation 
toxicity may cause fatigue, nausea, vomiting, anorexia, alopecia, and radiation dermatitis 
[112]. Where numerous repeat treatments are not feasible, a single fraction of 6–8 Gy may 
be considered, accepting a lower rate of tumour control and possibly greater acute toxicity. 
Alternatively, in patients with poor medical and/or functional status, supportive care alone 
may be the most appropriate management.
In this case, without focal neurologic deficits, limited intervention with a focus on patient 
comfort is a reasonable approach.
5. Conclusion
The brain is a common site of progression for patients with cancer, and brain metastases are 
associated with significant morbidity and mortality. Many modalities of treatment are avail-
able aimed at controlling neurologic progression and overall survival, as well as palliating 
symptoms. A thoroughly multidisciplinary approach is therefore required for comprehensive 
and effective management of brain metastases.
Figure 6. (A)–(C) T1 gadolinium contrast-enhanced MRI demonstrating cerebral atrophy and multiple metastases. 
(D) FLAIR sequence showing white-matter changes distinct from enhancing lesions.
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